Eligibility Criteria

DISEASE CHARACTERISTICS:

- Patients must have one of the following diagnoses and/or treatment plans:

- Newly diagnosed de novo AML

- First or subsequent relapse of AML

- Secondary AML

- Planned treatment as per COG-AAML0531 (including those in whom it is planned to
not administer Intensification III) or AAML1031 for any diagnosis; either those
following these treatment plans or those enrolled on AAML1031 are eligible

- Patients with the following diagnoses are not eligible:

- Acute promyelocytic leukemia (APL)

- Down syndrome

- Juvenile myelomonocytic leukemia (JMML)

PATIENT CHARACTERISTICS:

- Creatinine clearance or radioisotope GFR = 70 mL/min OR a serum creatinine based on
age/gender as follows:

- = 0.4 mg/dL (age 1 month to < 6 months)

- = 0.5 mg/dL (age 6 months to < 1 year)

- = 0.6 mg/dL (age 1 to < 2 years)

- = 0.8 mg/dL (age 2 to < 6 years)

- = 1 mg/dL (age 6 to < 10 years)

- = 1.2 mg/dL (age 10 to < 13 years)

- = 1.4 mg/dL (females age = 13 years)

- = 1.5 mg/dL (males age 13 to < 16 years)

- = 1.7 mg/dL (males age = 16 years)

- Total bilirubin = 1.5 x upper limit of normal (ULN) for age AND SGOT (AST) or SGPT
(ALT) < 2.5 x ULN

- Lactating patients must agree not to nurse a child while on this trial

- Female patients of childbearing age must have a negative pregnancy test

- Patients must agree to use an effective birth control method

- Patients with a documented history of IFI within the previous 30 days are not
eligible

- Patients with a history of echinocandin or fluconazole hypersensitivity are not
eligible

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No other concurrent systemic antifungal therapy